Estadístiques de Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models

Visites totals

views
Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models 143

Visites totals per mes

views
August 2024 4
September 2024 3
October 2024 0
November 2024 2
December 2024 0
January 2025 0
February 2025 0

Visites al fitxer

views
hernandez-mcr-nove.pdf(legacy) 147
hernandez-mcr-nove.pdf 20

Vistes principals per país

views
United States 79
Spain 19
Sweden 13
China 9
Ireland 6
Germany 4
South Korea 2
Belgium 1
Czechia 1
Iran 1
Italy 1
Mexico 1
Malaysia 1
Netherlands 1
Romania 1
Russia 1

Visites principals per ciutat

views
San Ramon 22
Fairfield 11
Mountain View 9
Shenzhen 8
Barcelona 7
Cambridge 5
Dublin 5
Ashburn 4
Menlo Park 3
Málaga 3
San Diego 3
Amorebieta 2
Boardman 2
Daejeon 2
Ann Arbor 1
Bucharest 1
Catania 1
Cupertino 1
Madrid 1
Mérida 1
Olesa De Montserrat 1
Premiá De Mar 1
Redwood City 1
Seattle 1
Shah Alam 1
Vitoria 1